Coripharma proudly announces the completion of the 16th dossier from its own development, marking a significant milestone in the company’s journey of innovation and excellence.
Lisdexamphetamine is based on the reference product Elvanse®, commonly prescribed for managing attention deficit disorder (ADHD).
This achievement is a testament to the outstanding efforts of the R&D team and the seamless collaboration within Coripharma. The timing couldn’t be better, as the secured DCP slot in January 2025 strategically positions our partners for successful market entry.
With this milestone, Coripharma reaffirms its dedication to development of high-quality generics and strengthens its global partnerships.
